Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenegermin in Persistent Corneal Epithelial Defect (PCED)
NCT07519902Phase 3Recruiting
- Sponsor
- Dompé
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
A Phase 3 trial of cenegermin in persistent corneal epithelial defect (PED), sponsored by Dompé. Started Jun 2026; status: recruiting.
02
Drugs
cenegermin
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT07519902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07519902.